One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia
Bruce S. Stambler, MD a , Francis Plat, MD b , Philip T. Sager, MD c , Veronica Lubkov, PhD b , Silvia Shardonofsky, MD b , Douglas Wight, MSc b , Michael Chen, PhD d , and A. John Camm, MD e Atlanta, GA; Quebec, Canada; Palo Alto, CA; Berkeley Heights, NJ; London, United Kingdom
doi : 10.1016/j.ahj.2022.06.005
Volume 253, November 2022, Pages 20-29
Targeted potassium levels to decrease arrhythmia burden in high risk patients with cardiovascular diseases (POTCAST): Study protocol for a randomized controlled trial
Ulrik Winsløw, MD a , Tharsika Sakthivel, MD a , Chaoqun Zheng, MD c , Helle Bosselmann, MD, PhD c , Ketil Haugan, MD, PhD c , Niels Bruun, MD, DMSc c,d , Charlotte Larroudé, MD, PhD b , Kasper Iversen, MD, DMSc b,d , Hillah Saffi, BSc med a , Emil Frandsen, BSc med a , Niels Risum, MD, PhD a , Henning Bundgaard, MD, DMSc a,d,# , and Christian Jøns, MD, PhD a,# Denmark
doi : /10.1016/j.ahj.2022.07.003
Volume 253, November 2022, Pages 59-66
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Nimish N. Shah, MD a , Lama Ghazi, MD, PhD b , Yu Yamamoto, MS b , Melissa Martin, MS b , Michael Simonov, MD b , Ralph J. Riello, PharmD b , Kamil F. Faridi, MD, MSc a , Tariq Ahmad, MD, MPH a,b , F. Perry Wilson, MD, MSCE a,b , and Nihar R. Desai, MD, MPH a,b New Haven, CT
doi : 10.1016/j.ahj.2022.07.002
Volume 253, November 2022, Pages 76-85
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Josephine Harrington, MD a,b , Jacob A. Udell, MD c , W. Schuyler Jones, MD a,b , Stefan D. Anker, MD PhD d,e , Deepak L. Bhatt, MD MPH f , Mark C. Petrie, MD g , Ola Vedin, MD h , Mikhail Sumin, MD i , Isabella Zwiener, PhD j , Adrian F. Hernandez, MD a,b , and Javed Butler, MD MPH MBA k,l Toronto, Canada; Wroclaw, Poland
doi : 10.1016/j.ahj.2022.05.010
Volume 253, November 2022, Pages 86-98
Safety and efficacy of exercise training in children and adolescents with congenital heart disease: A systematic review and descriptive analysis
Christopher A.J. Anderson, MPhil a , Jessica M. Suna, MSc a,b , Shelley E. Keating, PhD a , Rachael Cordina MBBS, PhD c,d,e , Derek L. Tran, BAppS c,d,e , Julian Ayer MBBS, PhD d,f , and Jeff S. Coombes, PhD a Queensland, Australia; New South Wales, Australia
doi : 10.1016/j.ahj.2022.06.006
Volume 253, November 2022, Pages 1-19
Deploying a novel custom mobile application for STEMI activation and transfer in a large healthcare system to improve cross-team workflow. STEMIcathAID implementation project
Haydee Garcia, NP a , Bernadette Springer, NP b , Andriy Vengrenyuk, MS a , Parasuram Krishnamoorthy, MD a , Derek Pineda, NP a , Brian Wasielewski, RN a , Wilfred AS Tan, RN a , Ashley D’Amiento, RN a , Julianna Bastone, BS c , Nitin Barman, MD a , Jeffrey Bander, MD d , Joseph Sweeny, MD a , George Dangas, MD, PhD a , Umesh Gidwani, MD a , Yuliya Vengrenyuk, PhD a , Ugo Ezenkwele, MD b , Abraham Warshaw, MD e , Atul Kukar, MD a , Kevin Chason, DO f , Michael Redlener, MD g , Matthew Bai, MD d , Jennifer Siller, DNP c , and Annapoorna S. Kini, MD a New York
doi : 10.1016/j.ahj.2022.06.008
Volume 253, November 2022, Pages 30-38
Differences in incident and recurrent myocardial infarction among White and Black individuals aged 35 to 84: Findings from the ARIC community surveillance study
Duygu Islek, MD, PhD, MPH a,b , Alvaro Alonso, MD, PhD a , Wayne Rosamond, PhD c , Anna Kucharska-Newton, PhD, MPH c , Yejin Mok, PhD, MPH d , Kunihiro Matsushita, MD, PhD d , Silvia Koton, PhD d,e , Michael Joseph Blaha, MD, MPH f , Mohammed K Ali, MD, MSc, MBA a,g,h , Amita Manatunga, PhD i , and Viola Vaccarino, MD, PhD a,j Atlanta, GA; Chapel Hill, NC
doi : 10.1016/j.ahj.2022.05.020
Volume 253, November 2022, Pages 67-75
Inflammation biomarkers and incident coronary heart disease: the Reasons for Geographic And Racial Differences in Stroke Study
Oluwasegun P. Akinyelure, MD, MPH, a , Lisandro D. Colantonio, MD, PhD, a , Ninad S. Chaudhary, MD, PhD, b , Byron C. Jaeger, PhD, c , Suzanne E. Judd, PhD, MPH, d , Mary Cushman, MD, MSc, e , Neil A. Zakai, MD, e , Edmond K. Kabagambe, DVM, MS, PhD, MBA, f,g , Virginia J. Howard, PhD, a , Monika M. Safford, MD, h , and Marguerite R. Irvin, PhD, a Birmingham, AL; Houston, TX; Burlington, VT; New Orleans, LA; New York, NY
doi : 10.1016/j.ahj.2022.07.001
Volume 253, November 2022, Pages 39-47
Individual inflammation biomarkers are associated with incident coronary heart disease (CHD) events. However, there is limited research on whether the risk for incident CHD is progressively higher with a higher number of inflammation biomarkers in abnormal levels.
Antiplatelet regimens following carotid artery revascularization
Megan Lee, BS a , Zain V. Ahmed, MD b , Jiaming Huang, MS b , Aaron Brice, MD b , Ahmad Arham, MD b , Yulanka Castro-Dominguez, MD b , Edouard Aboian, MD c , Sameer Nagpal, MD b , Kim G. Smolderen, PhD c,d , and Carlos Mena-Hurtado, MD b New Haven, CT; New Haven, CT; New Haven, CT; New Haven, CT;
doi : 10.1016/j.ahj.2022.07.004
Volume 253, November 2022, Pages 48-52
Dual antiplatelet therapy (DAPT) is indicated following carotid artery stenting (CAS) and single antiplatelet therapy (SAPT) following carotid endarterectomy (CEA), but it remains unknown how providers adhere to these guidelines in real-world clinical practice.
Six-lead device superior to single-lead smartwatch ECG in atrial fibrillation detection
Josca Scholten, BSc a,b , Ward P.J. Jansen, MD a , Thomas Horsthuis, MD, PhD a , Anuska D. Mahes, BSc a , Michiel M. Winter, MD, PhD b , Aeilko H. Zwinderman, PhD c , Jan T. Keijer, MD, PhD a , Madelon Minneboo, MD, PhD a,b , Joris R. de Groot, MD, PhD b , and Jouke P. Bokma, MD, PhD a,b North Holland, The Netherlands
doi : 10.1016/j.ahj.2022.06.010
Volume 253, November 2022, Pages 53-58
Corrigendum to “Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease� [Am Heart J (2021) 231:36–44]
Jay S. Shavadia, MD a,b , Jonathan Wilson, MS c , Daniel Edmonston, MD b,d , Alyssa Platt, MA b,c , Patti Ephraim, MPH e , Rasheeda Hall, MD, MBA, MHS b,d , Benjamin A. Goldstein, PhD b,c , L. Ebony Boulware, MD, MPH b,d , Eric Peterson, MD, MPH b,d , Jane Pendergast, PhD b,c , and Julia J. Scialla, MD, MHS b,d,f Saskatchewan, Canada; Durham, NC; Charlottesville, VA
doi : 10.1016/j.ahj.2022.06.009
Volume 253, November 2022, Pages 99-100
